What is Ocugen Inc?
Ocugen Inc, formerly HISTOGENICS CORPORATION, is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of a pipeline of therapies for eye conditions. The company offers a diversified ophthalmic portfolio that includes gene therapies, biologics, and small molecules, targeting a range of retinal and ocular surface disorders. The company uses its modifier gene therapy platform to treat genetically diverse hereditary retinal diseases and dry age-related macular degeneration (AMD) based on the core hormone receptor genes NR2E3 (OCU400) and RORA (OCU410), respectively. The company also develops biological therapies for the treatment of wet AMD, diabetic macular edema (DME) and diabetic retinopathy (OCU200), as well as retinitis pigmentosa (OCU100).
Ocugen has also been in the news for the past few months for his efforts to develop a vaccine for COVID-19.
Ocugen Stock: Why is it actually rising?
World Health Organization (WHO) to discuss whether to grant an emergency room for the Ocugen vaccine against COVID-19. There is speculation on social media that the WHO may have already given the green light to the vaccine internally, as WHO posted several documents on the vaccine on its website in the run-up to today's meeting. So we are currently seeing WHO euphoria for Ocugen!
The Ocugen share is very risky, it can go down a lot as well as up a lot. Up to 50% - 60% in both directions. Nevertheless, we recommend holding the share until mid-2022!